Evidence map›Paper›PMID 40235685›Full record

ArticleOncology letters2025

Regulatory SNP of TERT promoter accompanied by C228T and

Yoko Nakazato, Koichi Hirano, Tomoya Mitsuma, Yu Arimasu, Tatsuya Hirokawa, Tomohiro Chiba, Masachika Fujiwara, Ryota Tanaka, Haruhiko Kondo, Hiroshi Kamma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yoko NakazatoDepartment of General Thoracic and Thyroid Surgery, Kyorin University, School of Medicine, Tokyo 181-8611, Japan.
Koichi HiranoDepartment of General Thoracic and Thyroid Surgery, Kyorin University, School of Medicine, Tokyo 181-8611, Japan.
Tomoya MitsumaDepartment of General Thoracic and Thyroid Surgery, Kyorin University, School of Medicine, Tokyo 181-8611, Japan.
Yu ArimasuDepartment of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
Tatsuya HirokawaTokyo Medical Examiner's Office, Tokyo 112-0012, Japan.
Tomohiro ChibaDepartment of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 112-0012, Japan.
Masachika FujiwaraDepartment of Pathology, Kyorin University School of Medicine, Tokyo 181-8611, Japan.
Ryota TanakaDepartment of General Thoracic and Thyroid Surgery, Kyorin University, School of Medicine, Tokyo 181-8611, Japan.
Haruhiko KondoDepartment of General Thoracic and Thyroid Surgery, Kyorin University, School of Medicine, Tokyo 181-8611, Japan.
Hiroshi KammaNasu Institute of Medical Sciences, Kamma Memorial Hospital, Nasushiobara, Tochigi 325-0046, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the increased incidence of thyroid cancer due to enhanced precision of ultrasound technology and extensive utilization of puncture aspiration cytology, the mortality rate remains low, raising concerns about overdiagnosis. Papillary thyroid carcinoma (PTC) is the most common type, primarily diagnosed through cell nuclei examination. Recent advancements in identifying genetic mutations and tumor classification have refined diagnostic methods. Point mutations in the telomerase reverse transcriptase promoter (

Indexed as

C228TC250TPTCTERTpTrSNP

Identifiers

PMID40235685
PMCPMC11997643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.